N¹-(2-chloroquinazolin-4-yl)-N³,N³-dimethylpropane-1,3-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N¹-(2-chloroquinazolin-4-yl)-N³,N³-dimethylpropane-1,3-diamine
• 英文别名: N'-(2-chloro-quinazolin-4-yl)-N,N-dimethyl-propanediyldiamine；N'-(2-Chlor-chinazolin-4-yl)-N,N-dimethyl-propandiyldiamin；N-(2-chloroquinazolin-4-yl)-N',N'-dimethylpropane-1,3-diamine
• 化学式: C₁₃H₁₇ClN₄
• mdl: MFCD09726545
• 分子量: 264.758
• InChiKey: CQKRDWSKMWTGNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N¹-(2-chloroquinazolin-4-yl)-N³,N³-dimethylpropane-1,3-diamine 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 (E)-N1-(2-(2-((1-benzyl-1H-imidazol-2-yl)methylene)hydrazinyl)quinazolin-4-yl)-N3,N3-dimethylpropane-1,3-diamine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents

  摘要：

  Two series of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives were synthesized and evaluated for their cytotoxicity against H-460, HT-29, HepG2 and SGC-7901 cancer cell lines in vitro. Most compounds displayed moderate to excellent activity, with IC50 values ranging from 0.015 to 4.09 mu M against all tested cell lines, respectively. The most promising compound 9p (E)-2-(24(1-(2,3-dichlorobenzyl)-1H-imidazol-2-yl)methylene)hydrazinyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine with IC50 values of 0.031 mu M, 0.015 mu M, 0.53 mu M and 0.58 mu M, which was 4- to 224 times more active than references 10 and Iressa, had emerged as a lead for further structural modifications. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.05.039
• 作为产物：
  描述：

  邻氨基苯甲酸 在 三乙胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 18.25h， 生成 N¹-(2-chloroquinazolin-4-yl)-N³,N³-dimethylpropane-1,3-diamine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents

  摘要：

  Two series of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives were synthesized and evaluated for their cytotoxicity against H-460, HT-29, HepG2 and SGC-7901 cancer cell lines in vitro. Most compounds displayed moderate to excellent activity, with IC50 values ranging from 0.015 to 4.09 mu M against all tested cell lines, respectively. The most promising compound 9p (E)-2-(24(1-(2,3-dichlorobenzyl)-1H-imidazol-2-yl)methylene)hydrazinyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine with IC50 values of 0.031 mu M, 0.015 mu M, 0.53 mu M and 0.58 mu M, which was 4- to 224 times more active than references 10 and Iressa, had emerged as a lead for further structural modifications. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.05.039

文献信息

• [EN] QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE QUINAZOLINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：TROBIO THERAPEUTICS PTY LTD

  公开号：WO2021155426A1

  公开（公告）日：2021-08-12

  The present disclosure relates generally to a class of quinazoline compounds, compositions containing the same and the therapeutic use of the compounds in the treatment of cancer.

  本公开涉及一类喹唑啉化合物，包含该化合物的组合物以及化合物在癌症治疗中的治疗用途。
• Curd et al., Journal of the Chemical Society, 1947, p. 775,780
  作者：Curd et al.

  DOI：——

  日期：——
• Quinoline derivatives
  申请人：ICI LTD

  公开号：US02497347A1

  公开（公告）日：1950-02-14
• QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER
  申请人：Trobio Therapeutics Pty Ltd

  公开号：EP4100395A1

  公开（公告）日：2022-12-14
• [EN] RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RECEPTEURS
  申请人：——

  公开号：WO1997020823A2

  公开（公告）日：1997-06-12

  [EN] The invention relates to a compound of formula (I) in which the variables are as defined and/or a salt or a tautomer thereof; and relates to a method of treatment of disorders or diseases associated with NPY receptor subtype Y5, to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and to the manufacture of the compounds of formula (I) or a salt thereof.
  [FR] L'invention concerne un composé de la formule (I), dans laquelle les variables sont telles que définies, ainsi qu'un sel ou un tautomère de celui-ci. Elle concerne également une méthode de traitement des troubles et maladies associés au sous-type Y5 du récepteur du neuropeptide Y, des compositions pharmaceutiques comprenant un composé de la formule (I) ou un sel de celui-ci acceptable sur le plan pharmacologique, ainsi que la fabrication des composés de la formule (I) ou d'un sel de ceux-ci.